Automatycznie aktualizowany

Clinical Trials Radar

Below you will find currently recruiting clinical trials for cancer patients — one click lets you show only trials conducted in Poland. The list is automatically updated from the ClinicalTrials.gov database, and we translate descriptions into Polish.

This is not medical advice — consult your oncologist

Descriptions are automatically translated with AI assistance. Always verify details in the original on ClinicalTrials.gov and consult your treating physician.

1410
active trials
71
with Poland location
Last update
Jul 6, 2026, 03:00 AM
Filtered by therapy/drug: Sacituzumab govitecanClear

Znaleziono 11 z 1410 badań

RecruitingPhase II

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

NCT06161532ClinicalTrials.gov ↗

Background: Rare tumors of the genitourinary (GU) tract can appear in the kidney, bladder, ureters, and penis. Rare tumors are difficult to study because there are not enough people to conduct large trials for new treatments. Two drugs-sacituzumab govitecan (SG) and atezolizumab-are each approved to treat other cancers. Researchers want to find out if the two drugs used together can help people with GU. Objective: To test SG, either alone or combined with atezolizumab, in people with rare GU tumors. Eligibility: Adults aged 18 years and older with rare GU tumors. These may include high grade neuroendocrine carcinomas; squamous cell carcinoma of the bladder; primary adenocarcinoma of the bladder; renal medullary carcinoma; or squamous cell carcinoma of the penis. Design: Participants will be screened. They will have a physical exam with blood and urine tests. They will have tests of heart function. They will have imaging scans. They may need a biopsy: A small needle will be used to remove a sample of tissue from the tumor. Both SG and atezolizumab are given through a tube attached to a needle inserted into a vein in the arm. All participants will receive SG on days 1 and 8 of each 21-day treatment cycle. Some participants will also receive atezolizumab on day 1 of each cycle. Blood and urine tests, imaging scans, and other exams will be repeated during study visits. Treatment may continue for up to 5 years. Follow-up visits will continue for 5 more years.

Full details →
RecruitingPhase II

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

NCT05601440ClinicalTrials.gov ↗

This study is being done to answer the following question: Can testing breast cancer for DNA abnormalities or "biomarkers" help predict which patients are most likely to be helped by certain treatments? The pre-study screening is being done to test a sample of blood (or tumour tissue) for biomarkers to see if patients can participate in the study

Full details →
RecruitingPhase III

Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer

NCT05552001ClinicalTrials.gov ↗

ISIdE is an European, multicentric study that aims to assess the efficacy of Sacituzumab Govitecan (SG) in locally advanced or metastatic triple-negative breast cancer where the disease has progressed despite chemotherapy or within 6 months after the end of curative treatments in order to: 1. evaluate the treatment efficacy in less pretreated patients. 2. identify biomarkers that could predict response or resistance to the drug.

Full details →
RecruitingPhase II

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

NCT06263543ClinicalTrials.gov ↗

The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is to determine if SG is still effective specifically in people who have already received T-DXd.

Full details →
RecruitingPhase II

Scalp Cooling in MBC

NCT04986579ClinicalTrials.gov ↗

This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin. The name of the study interve

Full details →
RecruitingPhase IIIFemale only

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

NCT07461454ClinicalTrials.gov ↗

The study will evaluate the safety and efficacy of YL202, when compared with treatment of physician's choice (eribulin, capecitabine, vinorelbine, gemcitabine or sacituzumab govitecan) in participants with unresectable locally advanced, recurrent or metastatic hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer who had failed at least one line of chemotherapy.

Full details →

Frequently asked questions

What is a clinical trial?

It is a study of a new therapy or drug involving patients, conducted according to a strict protocol and under medical supervision. For many cancer patients, it provides access to therapies that are not yet standardly available.

Is participation in a clinical trial paid?

Participation is free for the patient — the costs of the tested treatment are covered by the trial sponsor. Some trials also reimburse travel and accommodation costs.

How to apply for a clinical trial abroad?

Start with the trial card in our Radar — you will find eligibility criteria and contact details of the center from ClinicalTrials.gov there. Contact is usually in English; if you need support, write to us.

radar.footerNote

Alerts for new trials →